Anti-Müllerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy

Gynecological Endocrinology

Volumn 29, Issue 4, 2013, Pages 357-360

  Iwase, Akira ^a,b   Sugita, Atsuko ^a,b   Hirokawa, Wakana ^a   Goto, Maki ^a,b   Nakahara, Tatsuo ^a   Kajiyama, Hiroaki ^a   Shibata, Kiyosumi ^a   Nagatomo, Yoshinari ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Anti M llerian hormone, chemotherapy; Fertility preserving surgery; Ovarian malignancies, ovarian reserve

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; PEPLEOMYCIN; VINBLASTINE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYSTECTOMY; DISEASE MARKER; FERTILITY PRESERVING SURGERY; GERM CELL TUMOR; HORMONE BLOOD LEVEL; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVARIAN RESERVE; OVARIECTOMY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURE; SALPINGOOOPHORECTOMY; SURGICAL TECHNIQUE; BLOOD; FEMALE; LAPAROSCOPY; OVARY FOLLICLE;

ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FERTILITY PRESERVATION; HUMANS; LAPAROSCOPY; OVARIAN FOLLICLE; OVARIAN NEOPLASMS; OVARIECTOMY;

EID: 84883138030     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.743008     Document Type: Article

References (21)

1. Wallace WH. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer 2011;117:2301-10.
2. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998;27:927-43.
3. Eskander RN, Randall LM, Berman ML, et al. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011;205:103-10.
4. Rasool N, Rose PG. Fertility-preserving surgical procedures for patients with gynecologic malignancies. Clin Obstet Gynecol 2010; 53:804-14.
5. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009;115:4118-26.
6. Lee MM, Donahoe PK, Hasegawa T, et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81:571-6.
7. de Vet A, Laven JS, de Jong FH, et al. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002; 77:357-62.
8. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod 2009;24:982-90.
9. Lie Fong S, Lugtenburg PJ, Schipper I, et al. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008;23:674-8.
10. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010;94:638-44.
11. Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod 2011;26:3297-302.
12. Hirokawa W, Iwase A, Goto M, et al. The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. Hum Reprod 2011;26:904-10.
13. Iwase A, Hirokawa W, Goto M, et al. Serum anti-Müllerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve. Fertil Steril 2010; 94:2846-29.
14. Park JY, Kim DY, Suh DS, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 2008;110:345-53.
15. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1-7.
16. Zanetta G, Chiari S, Rota S, et al. Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997;104:1030-5.
17. Morice P, Camatte S, El Hassan J, et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001;75:92-6.
18. Tangir J, Zelterman D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003;101:251-7.
19. Zanetta G, Bonazzi C, Cantu M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015-20.
20. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19:2658-64.
21. Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 2006; 100:185-91.